22 February 2021
Visiongain has published a new report on Batten Disease Treatment Market Report to 2031. Profiles of Leading Batten Disease Treatment Market players, Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Batten Disease Treatment Market Report Market was valued at US$XXX billion in 2021 and is projected to reach at a market value of US$XXX billion by 2031. The global Batten Disease Treatment market has been growing considerably owing to the rising incidence and prevalence rate of batten disease, technological advancement, and significant investment in the R&D process. Further, the growing clinical trials and increasing pipeline products coupled with the rising investment in R&D will create significant scope for the global Batten Disease Treatment market. However, the high cost of Batten Disease Treatment and lack of awareness in emerging economies such as China, India and Korea will affect the growth of the market.
COVID-19 Impact on the Global Batten Disease Treatment Market
The global Batten Disease Treatment market has been impacted by the COVID-19 pandemic. The pandemic caused turbulence in the global economy due to the series of lockdowns and stern social distancing measures. Initially, the COVID-19 was emerged in Wuhan city of China, in December 2019. Within few months it reached to more than 200 countries. According to worldometers, over 51.9 million cases of COVID-19 were registered till 11thNovember 2020, around the globe with over 1.28 million fatalities.
Rising incidence and prevalence of Batten Disease
Batten Disease Treatment are increasingly adopted around the globe owing to the growing incidence and prevalence rate of batten disease around the globe. For instance, around 4 out of every 100,000 children in the US suffers from the batten disease. NCL (Neuronal ceroid lipofuscinosis) diseases are rare but the incidence and prevalence rate of this type of batten disease is rising. The childhood onset variants of this disease are the most common neurodegenerative disorders that can affect more than one person in families that carry the defective genes.
Disposable income is increasing in emerging economies
Emerging economies such as Korea, Thailand, India, and China are on a roll in gaining traction owing to the growing disposable income and cohesive government regulations. The rising disposable income opened new opportunities for Batten Disease Treatment market players. The demand for the expensive treatment and products is increasing in these emerging economies. Batten Disease Treatmentis expensive that affects the price sensitive economies, however, with the increasing disposable income and improving healthcare system the global Batten Disease Treatment will get benefitted.
Cohesive government policies
Healthcare system is getting huge support from the governments around the globe. Cohesive policies and government support boosted the healthcare system of the world. For instance, the US spends over $10,000 per individual, which is the highest healthcare spending across the world. Other developed economies such as the UK, Germany, Canada, among others, injects significant amount of money in the healthcare system. Even the emerging economies including China, Korea, India, Korea, and Thailand are also increasing their healthcare spending.
Significant contribution from the market players
Batten Disease Treatment market players ReGenX Biosciences LLC, BioMarin Pharmaceuticals, Amicus Therapeutics, Abeona Therapeutics, Polaryx Therapeuticsare contributing significantly through investment in R&D, partnership, collaboration, among others to develop innovative drugs and treatment solutions in near future.
Significant funding in fight against the Batten Disease
Various government and non-profit organizations are moving from pillar to post to contribute to fight against the batten disease. For instance, BBDF (Beyond Batten Disease Foundations) have partnered with various Batten disease non-profits, research institutes, government advisories, pharmaceutical companies, regulatory experts, and other batten disease treatment market players in bid to fight against all neurodegenerative diseases. BBDF has so far received an overwhelming grant of over $100,000 to develop innovative treatment for Batten disease. BBDF work closely with other organizations such as BDSRA, NCL Foundation, Batten Disease Family Association, Contact Punt NCL, Hope for Bridget, Noah’s Hope, the European Task force on Brain and Neurodegenerative Lysosomal Storage Diseases.
Visiongain report covers detailed competitive landscape which includes overview of key players operating, extensive product portfolios, recent developments, among others. Some of the company’s profiled in this report include ReGenX Biosciences LLC, BioMarin Pharmaceuticals, Seneb BioSciences, Inc., Amicus Therapeutics, Abeona Therapeutics, Polaryx Therapeutics, Theranexus, Recursion Pharmaceuticals, Sanofi, Takeda Pharmaceuticals, StemCells, Inc., Antech Diagnostics, Neurogene Inc., Celgene Corp, Raptor Pharmaceutical Corp, among others. The global Batten Disease Treatment market players adopt various strategies to cater the available opportunities in the market. Rising investment in R&D, regular product launches, mergers & acquisitions, partnerships, collaborations, new product developments, and so on, are the key strategies adopted by the market players. For instance, on 12th December 2020, Theranexus and Beyond Batten Disease Foundation (BBDF) signed the partnership contract of the worldwide exclusive license for Batten disease drug candidate BBDF-101
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.